AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co- receptor

Nature Medicine

Volumn 4, Issue 1, 1998, Pages 72-77

  Donzella, George A ^a   Schols, Dominique ^b   Lin, Steven W ^a   Esté, José A ^b   Nagashima, Kirsten A ^c   Maddon, Paul J ^c   Allaway, Graham P ^c   Sakmar, Thomas P ^a   Henson, Geoffrey ^d   De Clercq, Erik ^b   Moore, John P ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c Clinical Research   (United States)

^d GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENE BIS(METHYLENE)] BIS 1,4,8,11 TETRA AZACYCLOTETRADECANE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS CELL TRANSFORMATION; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CALCIUM; CARBACHOL; CD4-POSITIVE T-LYMPHOCYTES; CELL FUSION; CELL LINE; CELLS, CULTURED; CHEMOKINES, CXC; CYTOKINES; HETEROCYCLIC COMPOUNDS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INTERLEUKIN-2; KINETICS; MEMBRANE FUSION; RANTES; RECEPTORS, CCR5; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 0031891516     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0198-072     Document Type: Article

References (49)

1. Feng, Y., Broder, C.C., Kennedy, P.E. & Berger, E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G protein coupled receptor. Science 272, 872-877 (1996).
2. Bleul, C.C. et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829-833 (1996).
3. Oberlin, E. et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382, 833-835 (1996).
4. Premack, B.A. & Schall, T.J. Chemokine receptors: Gateways to inflammation and infection. Nature Med. 2, 1174-1178 (1996).
5. Richman, D.D. & Bozzette, S.A. The impact of the syncytium inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169, 968-974 (1994).
6. Saag, M.S., Hammer, S.M. & Lange, J.M.A. Pathogenicity and diversity of HIV and implications for clinical management: A review. J. Acquir. Immune Defic. Syndr. 7 (Suppl.2), S2-S11 (1994).
7. Connor, R.I. & Ho, D.D. Human immunodeficiency virus type 1 variants with increased replication capacity develop during the asymptomatic stage before disease progression. J. Virol. 68, 4400-4408 (1994).
8. Zhu, T. et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261, 1179-1181 (1993).
9. Dragic, T. et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673 (1996).
10. Deng, H.K. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996).
11. Choe, H. et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 86, 1135-1148 (1996).
12. Doranz, B.J. et al. A dual-tropic, primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR 3, and CKR-2b as fusion cofactors. Cell 86, 1149-1159 (1996).
13. Alkhatib, G. et al. CC CKR5: A RANTES, MIP-lα, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996).
14. Simmons, G. et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70, 8355-8360 (1996).
15. Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S. & Landau, N.R. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185, 621-628 (1997).
16. Arenzana-Seisedos, F. et al. HIV blocked by chemokine antagonist. Nature 383, 400 (1996).
17. Simmons, G. et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276, 276-279 (1997).
18. De Clercq, E. et al. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. USA 89, 5286-5290 (1992).
19. De Clercq, E. et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38, 668-674 (1994).
20. De Vreese, K. et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70, 689-696 (1996).
21. De Vreese, K. et al. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res. 29, 209-219 (1996).
22. Chen, B.K., Saksela, K., Andino, R. & Baltimore, D. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 68, 654-660 (1994).
23. Hill, CM. et al. Envelope glycoproteins from HIV-1, HIV-2, and SIV can use human CCR5 as a cofactor for viral entry and make direct CD4-dependent interactions with this chemokine receptor, J. Virol. 71, 6296-6304 (1997).
24. Schols, D., Esté, J.A., Henson, G. & De Clercq, E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR4. Antiviral Res. 35, 147-156 (1997).
25. Litwin, V. et al. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. J. Virol. 70, 6437-6441 (1996).
26. Pantaleo, G. et al. Dissociation between syncytia formation and HIV spreading. Suppression of syncytia formation does not necessarily reflect inhibition of HIV infection. Eur. J. Immunol. 21, 1771-1774 (1993).
27. Layne, S.P., Merges, M.J., Spouge, J.L, Dembo, M & Nara, P.L. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J. Virol. 65, 3293-3300 (1991).
28. Sylwester, A., Murphy, S., Shutt, D. & Soll, D.R. HIV-induced T cell syncytia are self-perpetuating and the primary cause of T cell death in culture. J. Immunol. 158, 3996-4007 (1997).
29. Trkola, A. et al. CD4-dependent, antibody sensitive interactions between HIV-1 and its co-receptor CCR5. Nature 384, 184-186 (1996).
30. Wu, L. et al. CD4 induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179-183 (1996).
31. Moore, J.P. & Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 exterior envelope glycoprotein. J. Virol. 70, 1863-1872 (1996).
32. Endres, M.J. et al. CD4 independent infection by HIV-2 is mediated byfusin/CXCR4. Cell 87, 745-756 (1996).
33. Wu, L., et al. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 and a single domain for chemokine binding. J. Exp. Med, (in the press).
34. McKnight, A. et al. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J. Virol. 71, 1692-1696 (1997).
35. Strizki, J.M. et al. A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1 89.6 but not the T-tropic isolate HIV-1 HXB. J. Virol. 71, 5678-5691 (1997).
36. Lapham, C.K., et al. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 274, 602-605 (1996).
37. Hesselgesser, J., et al. CD4-independent association between HIV-1 gp120 and CXCR4: Functional chemokine receptors are expressed in human neurons. Current Biol. 7, 112-121 (1997).
38. Picard, L. et al. Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry. Virology 231, 105-111 (1997).
39. Potemya, S. et al. CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: The role of the N-terminal domain of CXCR-4 in fusion and entry. J. Virol. 71, 4419-4424 (1997).
40. Brelot, A. et al. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus co-receptor activity. J. Virol. 71, 4744-4751 (1997).
41. Monteclaro, F.S. & Charo, I.F. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1α receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem. 271, 19084-19092 (1996).
42. Wells, T.N.C. et al. Selectivity and antagonism of chemokine receptors. J. Leukocyte Biol. 59, 53-60 (1996).
43. Datema, R. et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. 40, 750-754 (1996).
44. Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-378 (1996).
45. Samson, M. et al. Resistance to HIV-1 infection of Caucasian individuals bearing mutant alleles of the CKR5 chemokine receptor gene. Nature 382, 722-725 (1996).
46. Nagasawa, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638 (1996).
47. Trkola, A. et al. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J. Virol. (in the press).
48. Koito, A., Stamatatos, L. & Cheng-Mayer, C. Small amino acid changes within the V2 domain can affect the function of a T-cell line tropic human immunodeficiency virus type 1 envelope gp120. Virology 206, 878-884 (1995).
49. Shibata, R. et al. Isolation and characterization of a syncytium inducing macrophage/T-cell line tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J. Virol. 69, 4453-4462 (1995).